Research Progress of Mechanisms and Drug Therapy For Atherosclerosis on Toll-Like Receptor Pathway

被引:13
作者
Yin, Qi-Yang [1 ]
Zhao, Bo [1 ]
Qiu, Yan-Ying [1 ]
Fei, Yu-Xiang [1 ]
Hu, Ya-Hui [2 ]
Li, Yun-Man [1 ]
机构
[1] China Pharmaceut Univ, Dept Physiol, State Key Lab Nat Med, Sch Basic Med & Clin Pharm, Nanjing, Peoples R China
[2] Nanjing Med Univ, Dept Pharm, Childrens Hosp, Nanjing, Peoples R China
关键词
atherosclerosis; toll-like receptors; inflammation; cardiovascular disease; NF-KAPPA-B; ATTENUATES ATHEROGENESIS; ENDOTHELIAL DYSFUNCTION; MACROPHAGE ACTIVATION; VASCULAR INFLAMMATION; CYTOKINE PRODUCTION; NUCLEOTIDE-BINDING; COLORECTAL-CANCER; SIGNALING PATHWAY; IMMUNE-RESPONSES;
D O I
10.1097/FJC.0000000000000738
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recent reports have established atherosclerosis (AS) as a major factor in the pathogenetic process of cardiovascular diseases such as ischemic stroke and coronary heart disease. Although the possible pathogenesis of AS remains to be elucidated, a large number of investigations strongly suggest that the inhibition of toll-like receptors (TLRs) alleviates the severity of AS to some extent by suppressing vascular inflammation and the formation of atherosclerotic plaques. As pattern recognition receptors, TLRs occupy a vital position in innate immunity, mediating various signaling pathways in infective and sterile inflammation. This review summarizes the available data on the research progress of AS and the latest antiatherosclerotic drugs associated with TLR pathway.
引用
收藏
页码:379 / 388
页数:10
相关论文
共 131 条
[51]   Toll-like receptors and innate immunity [J].
Kumar, Himanshu ;
Kawai, Taro ;
Akira, Shizuo .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2009, 388 (04) :621-625
[52]   Resveratrol improves endothelial dysfunction and attenuates atherogenesis in apolipoprotein E-deficient mice [J].
Li, Jinghua ;
Zhong, Zhenwei ;
Yuan, Jiru ;
Chen, Xiaohang ;
Huang, Ziyang ;
Wu, Zeyu .
JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2019, 67 :63-71
[53]   Potential Medications or Compounds Acting on Toll-like Receptors in Cerebral Ischemia [J].
Li, Man ;
Liu, Jing ;
Bi, Ying ;
Chen, Jixiang ;
Zhao, Lei .
CURRENT NEUROPHARMACOLOGY, 2018, 16 (02) :160-175
[54]  
Li Na, 2016, Zhongguo Zhong Yao Za Zhi, V41, P1706, DOI 10.4268/cjcmm20160922
[55]   Toll-like receptor 2 downregulates the cholesterol efflux by activating the nuclear factor-κB pathway in macrophages and may be a potential therapeutic target for the prevention of atherosclerosis [J].
Li, Yongqiang ;
Shen, Shuxin ;
Ding, Shoukun ;
Wang, Lixia .
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2018, 15 (01) :198-204
[56]   Taming Immune and Inflammatory Responses to Treat Atherosclerosis [J].
Libby, Peter ;
Hansson, Goran K. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (02) :173-176
[57]   Toll-like receptor 7 deficiency protects apolipoprotein E-deficient mice from diet-induced atherosclerosis [J].
Liu, Cong-Lin ;
Santos, Marcela M. ;
Fernandes, Cleverson ;
Liao, Mengyang ;
Iamarene, Karine ;
Zhang, Jin-Ying ;
Sukhova, Galina K. ;
Shi, Guo-Ping .
SCIENTIFIC REPORTS, 2017, 7
[58]   Toll-like receptor 2 plays a critical role in the progression of atherosclerosis that is independent of dietary lipids [J].
Liu, Xinyan ;
Ukai, Takashi ;
Yurnoto, Hiromichi ;
Davey, Michael ;
Goswami, Sulip ;
Gibson, Frank C., III ;
Genco, Caroline A. .
ATHEROSCLEROSIS, 2008, 196 (01) :146-154
[59]   Toll-like receptor 5 deficiency attenuates interstitial cardiac fibrosis and dysfunction induced by pressure overload by inhibiting inflammation and the endothelial-mesenchymal transition [J].
Liu, Yuan ;
Hu, Zhe-fu ;
Liao, Hai-han ;
Liu, Wei ;
Liu, Juan ;
Ma, Zhen-guo ;
Wu, Qing-qing ;
Xu, Man ;
Zhang, Ning ;
Zhang, Yao ;
Bian, Zhou-yan ;
Tang, Qi-zhu .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2015, 1852 (11) :2456-2466
[60]   TLRs are important inflammatory factors in atherosclerosis and may be a therapeutic target [J].
Liu, Yunfang ;
Yu, Huiming ;
Zhang, Yun ;
Zhao, Yuxia .
MEDICAL HYPOTHESES, 2008, 70 (02) :314-316